This study is the first to demonstrate that sodium butyrate treatment alleviates MP-induced hypertension and kidney disease in young rats, likely through reduced oxidative stress, altered gut microbiota, increased butyric acid, and enhanced renal GPR43 expression. Here, FFAR2 is linked to kidney disorder.